



261 Mountain View Dr
Colchester, VT 05446
License #: TLAB0030
802-767-7256
info@onwardanalytics.biz

Certificate of Analysis



Client Name: LC3 Incorporated

License Number: SCLT0391



Sample ID: 20251208-27292

Sample Name: HL: D, DS & SoS

Sample Lot: SCLT0391-02

Sample Matrix: Flower

Date Received: 12/8/2025

Date Reported: 12/15/2025

Date Tested: 12/9/2025



Pesticides

Pass

Residual pesticide analysis utilizing Liquid Chromatography – Mass Spectrometry (LC-MSMS; SOP-070-OA) - Limit units: ppm | Test ID: #89731

| Analyte | Pass/Fail | Result (ppm) | Limit | LOD (ppm) | LOQ (ppm) |
|---------------|-----------|--------------|---------|-----------|-----------|
| Abamectin B1a | Pass | ND | 0.10000 | 0.00687 | 0.02081 |
| Abamectin B1b | Pass | ND | 0.10000 | 0.00133 | 0.00405 |
| Acephate | Pass | ND | 0.10000 | 0.02214 | 0.06710 |
| Acequinocyl | Pass | ND | 0.10000 | 0.02276 | 0.06897 |
| Azoxystrobin | Pass | ND | 0.10000 | 0.01262 | 0.03825 |
| Bifenazate | Pass | ND | 0.10000 | 0.01232 | 0.03734 |
| Bifenthrin | Pass | ND | 3.00000 | 0.04612 | 0.13976 |
| Carbaryl | Pass | ND | 0.50000 | 0.01039 | 0.03149 |
| Chlorpyrifos | Pass | ND | 0.04000 | 0.00702 | 0.02128 |
| Cypermethrin | Pass | ND | 1.00000 | 0.02839 | 0.08604 |
| Etoazole | Pass | ND | 0.10000 | 0.00915 | 0.02772 |
| Imazalil | Pass | ND | 0.04000 | 0.00664 | 0.02012 |
| Imidacloprid | Pass | ND | 5.00000 | 0.02001 | 0.06063 |
| Myclobutanil | Pass | ND | 0.10000 | 0.01691 | 0.05123 |
| Spinosyn A | Pass | ND | 0.10000 | 0.00632 | 0.01916 |
| Spinosyn D | Pass | ND | 0.10000 | 0.00256 | 0.00775 |
| Pyrethrins | Pass | ND | 0.50000 | 0.00022 | 0.00072 |
| | | | | 0.00498 * | 0.00015 * |

* Pyrethrins action limit represents sum of isomers I & II

Callie Chapman

Callie Chapman
Lab Director
12/15/2025

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

